Global market grows at 6.3% CAGR through 2033 as demand rises for safer, targeted chemotherapy treatments worldwide.

An individualized neoantigen mRNA vaccine was tested in patients with early-stage triple-negative breast cancer and showed feasibility, safety, and strong T cell immune responses. Long-term follow-up ...

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that the Japan Patent Office (JPO) has issued a notice of allowance for Patent Application No. 2021-577862 ...

Highlights • Several antineoplastic drugs have been formulated in nanomedicines (nanodrugs) for chemotherapy. • Clinical response, overall survival, safety, and patients' quality of life are analyzed ...

Department of Clinical Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China Introduction: Doxorubicin (DOX) is a primary treatment for breast cancer (BC), but its ...

Platinum resistance remains a significant obstacle in the treatment of advanced-stage ovarian cancer, frequently leading to therapeutic failure. Our previous research identified Superoxide Dismutase 1 ...

While the primary end point of overall survival was not met in the phase 3 RESILIENT study, the overall response rate was 44.1% vs 21.6% with liposomal irinotecan vs topotecan in relapsed small cell ...

Phase II, Single-Arm Trial of Induction and Concurrent Vismodegib With Curative-Intent Radiation Therapy for Locally Advanced, Unresectable Basal Cell Carcinoma Patients with SCLC and progression on ...

A newly described small molecule inhibitor called AOH-1996 targets a cancer-associated isoform of PCNA (caPCNA), leading to a very broad therapeutic window.